A network pharmacology and molecular docking investigation on the mechanisms of Shanyaotianhua decoction (STT) as a therapy for psoriasis.

Chen Yue, Jiahao Feng, Aili Gao
Author Information
  1. Chen Yue: Institute of Dermatology, Guangzhou Medical University, Guangzhou, Guangdong, China. ORCID
  2. Jiahao Feng: The Seventh Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
  3. Aili Gao: Institute of Dermatology, Guangzhou Medical University, Guangzhou, Guangdong, China. ORCID

Abstract

Psoriasis is an immune-mediated inflammatory skin disease with a complex etiology involving environmental and genetic factors. Psoriasis patients often require long-term treatment. Shanyaotianua decoction (STT), a typical traditional Chinese medicine prescription, positively affects psoriasis, although its molecular targets remain unknown. To elucidate its molecular mechanisms, a combination of network pharmacology, bioinformatics analysis, and drug similarity comparisons were employed. Participants were separated into 3 groups: non-lesional (NL), lesions after medication (LM), and psoriasis lesion groups (LS). Based on the Gene Ontology/kyoto encyclopedia of genes and genomes enrichment analyses, the key targets were mainly enriched for biological processes (immuno-inflammatory responses, leukocyte differentiation, lipid metabolic disorders, and viral infection) with the relevant pathways (Janus kinase/signal transducers and activators of transcription and adipocytokine signaling and T-helper 17 cell differentiation), thus identifying the possible action mechanism of STT against psoriasis. Target prediction for 18 STT compounds that matched the screening criteria was performed. Then, the STT compounds were intersected with the differentially expressed genes of the psoriatic process, and 5 proteins were potential targets for STT. Based on the open-source toolkit RDKit and DrugBank database, and through molecular docking and drug similarity comparisons, spinasterol, diosgenin, and 24-Methylcholest-5-enyl-3belta-O-glucopyranoside_qt may be potential drugs for psoriasis.

References

  1. J Immunol. 2018 Sep 15;201(6):1605-1613 [PMID: 30181299]
  2. Front Immunol. 2019 Jun 25;10:1440 [PMID: 31293591]
  3. J Dermatol. 2018 Mar;45(3):264-272 [PMID: 29226422]
  4. J Clin Diagn Res. 2016 Aug;10(8):WL01-2 [PMID: 27656542]
  5. Mol Neurodegener. 2022 Sep 21;17(1):61 [PMID: 36131294]
  6. Complement Ther Med. 2016 Apr;25:55-60 [PMID: 27062949]
  7. J Eur Acad Dermatol Venereol. 2019 Jan;33(1):128-135 [PMID: 29953676]
  8. Chin Med. 2020 May 01;15:39 [PMID: 32377228]
  9. Front Immunol. 2019 Jul 31;10:1807 [PMID: 31417571]
  10. Front Endocrinol (Lausanne). 2020 Nov 10;11:553288 [PMID: 33244311]
  11. Br J Dermatol. 2006 Jul;155(1):62-6 [PMID: 16792753]
  12. J Dermatolog Treat. 2017 Feb;28(1):21-31 [PMID: 27366921]
  13. Evid Based Complement Alternat Med. 2016;2016:3164105 [PMID: 27822287]
  14. J Mol Graph. 1996 Feb;14(1):33-8, 27-8 [PMID: 8744570]
  15. J Ethnopharmacol. 2012 Jan 6;139(1):214-20 [PMID: 22100563]
  16. J Tradit Chin Med. 2006 Sep;26(3):198-201 [PMID: 17078451]
  17. Zhongguo Zhong Xi Yi Jie He Za Zhi. 1996 Mar;16(3):146-8 [PMID: 9208535]
  18. J Dermatolog Treat. 2016;27(2):114-9 [PMID: 26293108]
  19. Front Immunol. 2018 Jun 15;9:1323 [PMID: 29963046]
  20. Medicine (Baltimore). 2020 Sep 25;99(39):e22400 [PMID: 32991465]
  21. Front Pharmacol. 2021 Jan 22;11:599433 [PMID: 33551804]
  22. Int Immunopharmacol. 2010 Dec;10(12):1587-94 [PMID: 20933625]
  23. Clin Dermatol. 2007 Nov-Dec;25(6):616-24 [PMID: 18021900]
  24. J Leukoc Biol. 2009 Sep;86(3):557-66 [PMID: 19451397]
  25. Trials. 2014 Jul 22;15:294 [PMID: 25052161]
  26. Chin Med. 2018 Mar 23;13:16 [PMID: 29588654]
  27. Lancet. 2015 Sep 5;386(9997):983-94 [PMID: 26025581]
  28. Clin Exp Dermatol. 2000 Jan;25(1):57-61 [PMID: 10671976]
  29. Nucleic Acids Res. 2010 Jul;38(Web Server issue):W609-14 [PMID: 20430828]
  30. Int J Dermatol. 2014 Nov;53(11):1305-18 [PMID: 25208594]
  31. Life Sci. 2016 Jul 15;157:97-106 [PMID: 27234894]
  32. J Diabetes Res. 2022 Oct 6;2022:2736504 [PMID: 36248223]
  33. Br J Dermatol. 2009 May;160(5):929-37 [PMID: 19309365]
  34. Int Immunopharmacol. 2010 Sep;10(9):1047-54 [PMID: 20601188]
  35. Proc Natl Acad Sci U S A. 2014 Jul 22;111(29):10666-71 [PMID: 24994901]
  36. J Allergy Clin Immunol. 2019 Sep;144(3):750-763 [PMID: 31129129]
  37. Comb Chem High Throughput Screen. 2009 Jun;12(5):497-506 [PMID: 19519329]
  38. Dermatology. 2019;235(2):91-100 [PMID: 30566935]
  39. JAMA. 2020 May 19;323(19):1945-1960 [PMID: 32427307]
  40. Evid Based Complement Alternat Med. 2020 Apr 28;2020:5239854 [PMID: 32419809]
  41. J Invest Dermatol. 2015 Apr;135(4):1025-1032 [PMID: 25525775]
  42. J Exp Med. 2007 Dec 24;204(13):3183-94 [PMID: 18039949]
  43. Mol Med Rep. 2018 Sep;18(3):2733-2743 [PMID: 30015892]
  44. Immunity. 2013 Dec 12;39(6):1171-81 [PMID: 24332034]
  45. Int J Mol Sci. 2020 Jan 16;21(2): [PMID: 31963372]
  46. Biochem J. 1981 Feb 1;193(2):589-605 [PMID: 7030312]
  47. Chin Med. 2021 Dec 20;16(1):138 [PMID: 34930402]
  48. J Cheminform. 2020 Sep 1;12(1):51 [PMID: 33431044]
  49. Eur J Dermatol. 2012 Sep-Oct;22(5):663-7 [PMID: 22910173]
  50. J Cheminform. 2014 Apr 16;6:13 [PMID: 24735618]
  51. Dermatoendocrinol. 2011 Jul;3(3):130-5 [PMID: 22110772]
  52. Int J Mol Sci. 2019 May 07;20(9): [PMID: 31067781]
  53. Genetika. 2011 Sep;47(9):1254-61 [PMID: 22117411]
  54. Actas Dermosifiliogr (Engl Ed). 2019 Jan - Feb;110(1):12-19 [PMID: 30509759]
  55. Medicine (Baltimore). 2020 May;99(19):e20172 [PMID: 32384509]
  56. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082 [PMID: 29126136]
  57. Front Pharmacol. 2019 Jul 11;10:743 [PMID: 31379563]
  58. J Transl Med. 2016 May 10;14(1):130 [PMID: 27165166]
  59. Int J Mol Sci. 2019 Sep 05;20(18): [PMID: 31491865]
  60. Psoriasis (Auckl). 2016 Feb 22;6:7-32 [PMID: 29387591]
  61. J Invest Dermatol. 2011 Dec;131(12):2428-37 [PMID: 21881584]

MeSH Term

Humans
Network Pharmacology
Molecular Docking Simulation
Psoriasis
Dermatitis
Computational Biology

Word Cloud

Created with Highcharts 10.0.0STTpsoriasismoleculartargetsPsoriasisdecoctionmechanismsnetworkpharmacologydrugsimilaritycomparisonsBasedgenesdifferentiationcompoundspotentialdockingimmune-mediatedinflammatoryskindiseasecomplexetiologyinvolvingenvironmentalgeneticfactorspatientsoftenrequirelong-termtreatmentShanyaotianuatypicaltraditionalChinesemedicineprescriptionpositivelyaffectsalthoughremainunknownelucidatecombinationbioinformaticsanalysisemployedParticipantsseparated3groups:non-lesionalNLlesionsmedicationLMlesiongroupsLSGeneOntology/kyotoencyclopediagenomesenrichmentanalyseskeymainlyenrichedbiologicalprocessesimmuno-inflammatoryresponsesleukocytelipidmetabolicdisordersviralinfectionrelevantpathwaysJanuskinase/signaltransducersactivatorstranscriptionadipocytokinesignalingT-helper17cellthusidentifyingpossibleactionmechanismTargetprediction18matchedscreeningcriteriaperformedintersecteddifferentiallyexpressedpsoriaticprocess5proteinsopen-sourcetoolkitRDKitDrugBankdatabasespinasteroldiosgenin24-Methylcholest-5-enyl-3belta-O-glucopyranoside_qtmaydrugsinvestigationShanyaotianhuatherapy

Similar Articles

Cited By